CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer’s disease gene expression linked to neuropathology
Science Advances · 03.03.2023 · 9 (9)
DOI: 10.1126/sciadv.add2671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 03.03.2023. Verfasst von Cláudio Gouveia Roque und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NICHD NIH HHS, NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Gene expression is changed by disease, but how these molecular responses arise and contribute to pathophysiology remains less understood. We discover that β-amyloid, a trigger of Alzheimer’s disease (AD), promotes the formation of pathological CREB3L2-ATF4 transcription factor heterodimers in neurons. Through a multilevel approach based on AD datasets and a novel chemogenetic method that resolves the genomic binding profile of dimeric transcription factors (ChIPmera), we find that CREB3L2-ATF4 activates a transcription network that interacts with roughly half of the genes differentially expressed in AD, including subsets associated with β-amyloid and tau neuropathologies. CREB3L2-ATF4 activation drives tau hyperphosphorylation and secretion in neurons, in addition to misregulating the retromer, an endosomal complex linked to AD pathogenesis. We further provide evidence for increased heterodimer signaling in AD brain and identify dovitinib as a candidate molecule for normalizing β-amyloid–mediated transcriptional responses. The findings overall reveal differential transcription factor dimerization as a mechanism linking disease stimuli to the development of pathogenic cellular states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
- Integrated Program in Cellular, Molecular, and Biomedical Studies, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
- Division of Aging and Dementia, Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
- Doctoral Program in Neurobiology and Behavior, Columbia University, New York, NY, USA.
- Achucarro Basque Center for Neuroscience, Leioa, Spain.
- IKERBASQUE Basque Foundation for Science, Bilbao, Spain.
ORCID-Profile: Cláudio Gouveia Roque, Kyung Min Chung, Krystal Herline-Killian, Jimena Baleriola, Ulrich Hengst
Förderung
- NINDS NIH HHS
- NICHD NIH HHS
- NIA NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Gouveia Roque, C., Chung, K. M., McCurdy, E. P., Jagannathan, R., Randolph, L. K., Herline-Killian, K., Baleriola, J., & Hengst, U. (2023). CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer’s disease gene expression linked to neuropathology. Science Advances, 9(9). https://doi.org/10.1126/sciadv.add2671
Vancouver
Gouveia Roque C, Chung KM, McCurdy EP, Jagannathan R, Randolph LK, Herline-Killian K, et al. CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer’s disease gene expression linked to neuropathology. Science Advances. 2023;9(9). doi:10.1126/sciadv.add2671
BibTeX
@article{GouveiaRoque2023,
author = {Gouveia Roque, Cláudio and Chung, Kyung Min and McCurdy, Ethan P and Jagannathan, Radhika and Randolph, Lisa K and Herline-Killian, Krystal and Baleriola, Jimena and Hengst, Ulrich},
title = {CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer’s disease gene expression linked to neuropathology},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {9},
doi = {10.1126/sciadv.add2671}
}
EUVIMED